1. U.S. Food and Drug Administration (FDA), Mifeprex (mifepristone) information, 2018, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-a….
2. National Abortion Federation, 2020 Clinical Policy Guidelines for Abortion Care, Washington, DC: National Abortion Federation, 2020, https://prochoice.org/providers/quality-standards/.
3. Jones R and Boonstra H, The public health implications of the FDA’s update to the medication abortion label, Health Affairs Blog, 2016, http://healthaffairs.org/blog/2016/06/30/the-public-health-implications….
4. FDA, Questions and answers on Mifeprex, 2019, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-a….
5. Raymond EG et al., First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review, Contraception, 2013, 87(1):26–37, https://www.contraceptionjournal.org/article/S0010-7824(12)00643-9/fulltext.
6. Chen MJ and Creinin MD, Mifepristone with buccal misoprostol for medical abortion: a systematic review, Obstetrics & Gynecology, 2015, 126(1):12–21, https://escholarship.org/uc/item/0v4749ss.
7. FDA, Risk Evaluation and Mitigation Strategy (REMS) for single shared system mifepristone 200 mg, 2019, https://www.accessdata.fda.gov/drugsatfda_docs/rems/Mifepristone_2019_0….
8. Mifeprex REMS Study Group, Sixteen years of overregulation: time to unburden Mifeprex, New England Journal of Medicine, 2017, 376(8):790–794, https://www.nejm.org/doi/full/10.1056/NEJMsb1612526.
9. Raymond EG, Chong E and Hyland P, Increasing access to abortion with telemedicine, JAMA Internal Medicine, 2016, 176(5):585–586, http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2….
10. American Civil Liberties Union (ACLU),Federal court blocks FDA restriction that unnecessarily imposes COVID-19 risks on patients seeking abortion care, news release, New York: ACLU, July 13, 2020, https://www.aclu.org/press-releases/federal-court-blocks-fda-restrictio….
11. National Academies of Sciences, Engineering and Medicine, The Safety and Quality of Abortion Care in the United States, Washington, DC: National Academies Press, 2018.
12. Jones RK, Witwer E and Jerman J, Abortion Incidence and Service Availability in the United States, 2017, New York: Guttmacher Institute, 2019, https://www.guttmacher.org/report/abortion-incidence-service-availabili….
13. World Health Organization, Expanding Health Worker Roles for Safe Abortion in the First Trimester of Pregnancy, 2016, http://apps.who.int/iris/bitstream/10665/206191/1/WHO_RHR_16.02_eng.pdf.
14. Donovan M, Improving access to abortion via telehealth, Guttmacher Policy Review, 2019, 22:23–28, https://www.guttmacher.org/gpr/2019/05/improving-access-abortion-telehe….
15. FAIR Health, FH Healthcare Indicators and FH Medical Price Index 2019: An Annual View of Place of Service Trends and Medical Pricing, New York: FAIR Health, 2019, https://www.fairhealth.org/publications/whitepapers.
16. Kvedar J, Joel Coye M and Everett W, Connected health: a review of technologies and strategies to improve patient care with telemedicine and telehealth, Health Affairs, 2014, 33(2):194–199, https://www.healthaffairs.org/doi/10.1377/hlthaff.2013.0992.
17. American Medical Association, Council on Medical Service, Coverage of and payment for telemedicine, Report 7-A-14, 2014, http://www.modernhealthcare.com/assets/pdf/CH95086612.PDF.
18. Lawrence HC, Testimony of the American Congress of Obstetricians and Gynecologists (ACOG), submitted to U.S. Senate Committee on the Judiciary, S. 1696, The Women’s Health Protection Act hearing, July 15, 2014, https://www.actforwomen.org/wp-content/uploads/2015/09/ACOG-Testimony-W….
19. Jones RK and Jerman J, Time to Appointment and Delays in Accessing Care Among U.S. Abortion Patients, New York: Guttmacher Institute, 2016, https://www.guttmacher.org/report/delays-in-accessing-care-among-us-abo….
20. Raymond EG et al., Commentary: no-test medication abortion: a sample protocol for increasing access during a pandemic and beyond, Contraception, 2020, 101(6):361–366, https://www.contraceptionjournal.org/article/S0010-7824(20)30108-6/fulltext.
21. D’Almeida K, Telemedicine abortion care is coming to Maine, Rewire.News, Feb. 29, 2016, https://rewire.news/article/2016/02/29/telemedicine-abortion-care-coming-maine/.
22. Kohn JE et al., Medication abortion provided through telemedicine in four U.S. states, Obstetrics & Gynecology, 2019, 134(2):343–350, doi:10.1097/AOG.0000000000003357.
23. Boonstra HD and Nash E, A surge of state abortion restrictions puts providers—and the women they serve—in the crosshairs, Guttmacher Policy Review, 2014, 17(1):9–15, https://www.guttmacher.org/gpr/2014/03/surge-state-abortion-restrictions-puts-providers-and-women-they-serve-crosshairs.
24. Raymond E et al., TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States, Contraception, 2019, 100(3):173–177, https://www.contraceptionjournal.org/article/S0010-7824(19)30176-3/abstract.
25. Grossman D and Grindlay K, Safety of medical abortion provided through telemedicine compared with in person, Obstetrics & Gynecology, 2017, 130(4):778–782, https://journals.lww.com/greenjournal/Fulltext/2017/10000/Safety_of_Med….
26. Jerman J, Onda T and Jones RK, “What are people looking for when they Google ‘self-abortion’?”, Contraception, 2018, 97(6):510–514, https://www.contraceptionjournal.org/article/S0010-7824(18)30068-4/fulltext.
27. Kapp N et al., A research agenda for moving early medical pregnancy termination over the counter, BJOG, 2017, 124(11):1646–1652, http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14646/full.
28. Graham R, A new front in the war over reproductive rights: “abortion-pill reversal,” New York Times Magazine, July 18, 2017, https://www.nytimes.com/2017/07/18/magazine/a-new-front-in-the-war-over….
29. Delgado G and Davenport ML, Progesterone use to reverse the effects of mifepristone, Annals of Pharmacotherapy, 2012, 46(12):1723.
30. Grossman D et al., Continuing pregnancy after mifepristone and “reversal” of first-trimester medical abortion: a systematic review, Contraception, 2015, 92(3):206–211.
31. ACOG, Facts are important: Medication abortion “reversal” is not supported by science, 2017, https://www.acog.org/advocacy/facts-are-important/medication-abortion-r… .
32. Delgado G et al., A case series detailing the successful reversal of the effects of mifepristone using progesterone, Issues in Law & Medicine, 2018, 33(1):3–14.
33. Creinin MD et al., Mifepristone antagonization with progesterone to prevent medical abortion: a randomized controlled trial, Obstetrics and Gynecology, 2019, 135(1):158–165, https://journals.lww.com/greenjournal/Citation/2020/01000/Mifepristone_….
34. Louisiana Department of Public Health, Legislative Report on 2016 House Concurrent Resolution 87, 2017, http://www.dhh.louisiana.gov/assets/docs/LegisReports/HCR87RS20161.pdf.